ArticleJournal of cancer research and clinical oncology2008
Inhibition of osteopontin dependent carcinogenesis.
Article in Journal of cancer research and clinical oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Selenium as a Bioactive Micronutrient in the Human Diet and Its Cancer Chemopreventive Activity.Nutrients · 2021Review
- Osteopontin at the Crossroads of Inflammation and Tumor Progression.Mediators of inflammation · 2017Review
- Microdialysis combined with proteomics for protein identification in breast tumor microenvironment in vivo.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2010Article
- Total synthesis of all (-)-Agelastatin alkaloids.Chemical science · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteopontin is a molecule that promotes cellular proliferation as well as metastasis and plays a major role in the evolution of most systemic malignancies. Inhibition of carcinogenetic mechanisms that involve osteopontin will undoubtedly go a long way in controlling the growth of these tumors. A number of new molecules such as argatroban agelastatin A and selenium have been identified in this regard. For instance, Schulze et al. (in Breast Cancer Res Treat) have recently reported the successful utilization of argatroban for decreasing the growth of breast cancer tumor cells as well as their lymphatic metastasis. Similarly, anti osteopontin antibodies and antisense osteopontin RNA have been successfully used to inhibit tumor growth in prostate carcinomas and osteosarcomas, respectively. There is a clear and urgent need to expand the use of these molecules as well as to further identify other potent inhibitors of osteopontin mediated tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.